- Conditions
- Lung Cancer
- Interventions
- gemcitabine hydrochloride, oxaliplatin
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 2
- States / cities
- Miami, Florida • Tampa, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 868
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Grade I Neuroendocrine Carcinoma, Grade II Neuroendocrine Carcinoma, Grade III Neuroendocrine Carcinoma, Metastatic Neuroendocrine Carcinoma, Neuroendocrine Carcinoma, Recurrent Small Cell Lung Carcinoma, Refractory Small Cell Lung Carcinoma, Lung Cancer Stage IV, Large Cell Neuroendocrine Carcinoma, Neuroendocrine Tumors, Small Cell Lung Cancer Metastatic, Small-cell Lung Cancer
- Interventions
- Nivolumab, Temozolomide
- Biological · Drug
- Lead sponsor
- Dwight Owen
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 2
- States / cities
- Columbus, Ohio
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- docetaxel, placebo, nintedanib
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 9
- States / cities
- Chandler, Arizona • Fayetteville, Arkansas • Highland, California + 6 more
- Conditions
- Lung Cancer
- Interventions
- topotecan hydrochloride, vinorelbine tartrate
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Cancer, Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Cofetuzumab Pelidotin
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Springdale, Arkansas • Stanford, California + 8 more
- Conditions
- Malignant Mesothelioma
- Interventions
- PTK787/ZK 222584
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 80
- States / cities
- Anniston, Alabama • Birmingham, Alabama • La Jolla, California + 58 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Docetaxel, Radiation
- Drug · Radiation
- Lead sponsor
- Susanne Arnold
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer
- Interventions
- LMB-9 immunotoxin
- Biological
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2003
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Bethesda, Maryland
- Conditions
- Small Cell Lung Cancer
- Interventions
- DS-3201b, irinotecan
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Melanoma (Skin), Metastatic Cancer
- Interventions
- sargramostim
- Biological
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2012
- U.S. locations
- 87
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 54 more
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Interventions
- docetaxel, pemetrexed disodium, gemcitabine hydrochloride, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Lung Cancer
- Interventions
- trastuzumab, carboplatin, paclitaxel
- Biological · Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2004
- U.S. locations
- 68
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 51 more
- Conditions
- Lung Cancer
- Interventions
- celecoxib
- Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
- Interventions
- Cisplatin, CT, Docetaxel, FDG, FLT, PET/CT, Surgery
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 19 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Columbus, Ohio
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Interventions
- cisplatin, carboplatin, questionnaire administration
- Drug · Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- Not listed
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 2
- States / cities
- Syracuse, New York • Winston-Salem, North Carolina
- Conditions
- Lung Diseases, Cancer
- Interventions
- Combination Treatment - Cohort 1, Combination Treatment - Cohort 2, Combination Treatment - Cohort 3, Combination Treatment - Cohort 4
- Drug
- Lead sponsor
- New Mexico Cancer Research Alliance
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Colorectal Cancer, Triple Negative Breast Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, Head and Neck Cancer, Ovarian Cancer, Lymphoma, Sarcoma, Bladder Cancer, Melanoma, IDH1 Mutated Solid Tumors, IDH1 Mutated or MGMT Methylated Recurrent HGG (Not Recruiting)
- Interventions
- Toca 511, Toca FC
- Biological · Drug
- Lead sponsor
- Tocagen Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 3
- States / cities
- Denver, Colorado • Miami, Florida • Houston, Texas
- Conditions
- Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer
- Interventions
- docetaxel, AZD4547
- Drug
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 25 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Baltimore, Maryland + 2 more
- Conditions
- Adenocarcinoma of the Lung, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Interventions
- erlotinib hydrochloride, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Lung Cancer, Malignant Mesothelioma, Metastatic Cancer, Thymoma and Thymic Carcinoma
- Interventions
- radiofrequency ablation
- Procedure
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Carcinoma, Non-small Cell Lung
- Interventions
- REOLYSIN®, Carboplatin, Paclitaxel
- Biological · Drug
- Lead sponsor
- Oncolytics Biotech
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Columbus, Ohio
- Conditions
- Malignant Mesothelioma
- Interventions
- Antineoplaston therapy (Atengenal + Astugenal)
- Drug
- Lead sponsor
- Burzynski Research Institute
- Other
- Eligibility
- 1 Year to 120 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2005
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer, Lung Cancer, Lymphoma, Pancreatic Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- fluorouracil, gemcitabine hydrochloride, leucovorin calcium
- Drug
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2004
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Breast Neoplasm, Metastatic Malignant Digestive System Neoplasm, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Recurrent Brain Neoplasm, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Memantine, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery, Whole-Brain Radiotherapy
- Procedure · Drug · Other + 1 more
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 79
- States / cities
- Tucson, Arizona • Corona, California • Duarte, California + 63 more